Nobre-Cardoso João, Champion Emmanuelle, Darugar Adil, Fel Audrey, Lehoang Phuc, Bodaghi Bahram
a Département Hospitalo-Universitaire Vision and Handicaps 'ViewMaintain' , Pitié-Salpêtrière University Hospital , Paris , France.
b Department of Ophthalmology , Hospital Garcia de Orta E.P.E , Almada , Portugal.
Ocul Immunol Inflamm. 2017 Aug;25(4):447-454. doi: 10.3109/09273948.2015.1132738. Epub 2016 Mar 22.
To describe the clinical outcome of phakic eyes with macular edema (ME) due to non-infectious uveitis treated with a dexamethasone intravitreal implant.
A retrospective analysis of 41 eyes treated with a total of 58 dexamethasone intravitreal implants was conducted. Best corrected visual acuity (BCVA), central retinal thickness (CRT) and complications data were collected.
One month after the first implant, even as CRT improved significantly in most eyes (p<0.001), 31.7% showed no improvement in BCVA. At 6 months post-implantation, CRT and BCVA had deteriorated in up to 70% of patients. Thirteen eyes were re-implanted, with a similar effect to that of the first implant. Ocular hypertension developed in 36.2% of eyes, and three eyes had cataract surgery, all in eyes with repeated implants.
The dexamethasone intravitreal implant can be safely used to treat ME due to non-infectious uveitis, but with a limited and short effect on BCVA.
描述使用地塞米松玻璃体内植入物治疗非感染性葡萄膜炎所致黄斑水肿（ME）的有晶状体眼的临床结局。
对41只眼共使用58次地塞米松玻璃体内植入物进行回顾性分析。收集最佳矫正视力（BCVA）、视网膜中央厚度（CRT）及并发症数据。
首次植入后1个月，多数眼的CRT显著改善（p<0.001），但31.7%的眼BCVA无改善。植入后6个月，高达70%的患者CRT和BCVA恶化。13只眼再次植入，效果与首次植入相似。36.2%的眼发生高眼压，3只眼接受白内障手术，均为多次植入的眼。
地塞米松玻璃体内植入物可安全用于治疗非感染性葡萄膜炎所致的ME，但对BCVA的效果有限且持续时间短。
